Lantidra (donislecel) - MEDICAID - FLORIDA

This policy covers Lantidra (donislecel), an allogeneic (deceased-donor) pancreatic islet cell therapy delivered as an intraportal (hepatic portal vein) infusion for treatment of type 1 diabetes. Coverage is limited to adults aged 18–65 with T1D who have recurrent severe hypoglycemia or hypoglycemia unawareness or cannot achieve glycemic targets despite intensive insulin therapy, requires concomitant immunosuppression and medical director review, and allows repeat infusion only when specified clinical criteria (e.g., failure to achieve or loss of insulin independence within one year) are met.

"Diabetes mellitus (DM) is a complex endocrine disorder characterized by hyperglycemia (abnormally high levels of glucose)."

Sign up to see full coverage criteria, indications, and limitations.